{"nctId":"NCT02083380","briefTitle":"Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.","startDateStruct":{"date":"2014-07"},"conditions":["Uncomplicated Plasmodium Falciparum Malaria"],"count":448,"armGroups":[{"label":"A) Artefenomel 800mg: piperaquine 640mg","type":"EXPERIMENTAL","interventionNames":["Drug: Artefenomel 800mg: piperaquine 640mg"]},{"label":"B) Artefenomel 800mg: piperaquine 960mg","type":"EXPERIMENTAL","interventionNames":["Drug: Artefenomel 800mg: piperaquine 960mg"]},{"label":"C) Artefenomel 800mg: piperaquine 1440mg","type":"EXPERIMENTAL","interventionNames":["Drug: Artefenomel 800mg: piperaquine 1440mg"]}],"interventions":[{"name":"Artefenomel 800mg: piperaquine 640mg","otherNames":["OZ439 ; PQP"]},{"name":"Artefenomel 800mg: piperaquine 960mg","otherNames":["OZ439 ; PQP"]},{"name":"Artefenomel 800mg: piperaquine 1440mg","otherNames":["OZ439 ; PQP"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Male or female patient age \\>6 months \\<70 years.\n2. Body weight \\>5 kg \\<90 kg.\n3. Presence of mono-infection of P. falciparum with:\n\n   1. Fever, as defined by axillary temperature ≥ 37.5°C or oral/rectal/tympanic temperature ≥ 38°C, or history of fever in the previous 24 hours (history of fever must be documented) and,\n   2. Microscopically confirmed parasite infection, in range 1,000 to 100,000 asexual parasites /µL of blood.\n4. Written informed consent provided by the adult patient, or parent or legally acceptable representative (LAR) of the minor patient or by an impartial witness (if the patient or patient's LAR is illiterate), and by the medically qualified Investigator. Children will be asked to provide assent where appropriate. The age from which this will be sought will be defined by local legislation.\n\nExclusion Criteria:\n\n1. Presence of severe malaria (according to World Health Organization (WHO) definition - WHO 2013)\n2. Anti-malarial treatment:\n\n   1. With piperaquine -based compound, mefloquine, naphthoquine or sulphadoxine/pyrimethamine (SP) within the previous 6 weeks (after their inhibition of new infections has fallen below 50%).\n   2. With amodiaquine or chloroquine within the previous 4 weeks.\n   3. With quinine, halofantrine, lumefantrine-based compounds and any other anti-malarial treatment or antibiotics with anti-malarial activity (including cotrimoxazole, tetracyclines, quinolones and fluoroquinolones, and azithromycin) within the past 14 days.\n   4. With any herbal products or traditional medicines, within the past 7 days.\n3. Known history or evidence of clinically significant disorders such as, respiratory (including active tuberculosis), hepatic, renal, gastrointestinal, immunological, neurological (including auditory), endocrine, infectious, malignancy, psychiatric, history of convulsions or other abnormality (including head trauma).\n4. Family history of sudden death or of congenital or clinical conditions known to prolong QTcB or QTcF interval or e.g. patients with a history of symptomatic cardiac arrhythmias, with clinically relevant bradycardia or with severe cardiac disease.\n5. History of symptomatic cardiac arrhythmias or with clinically relevant bradycardia.\n6. Any predisposing cardiac conditions for arrhythmia such as severe hypertension, left ventricular hypertrophy (including hypertrophic cardiomyopathy) or congestive cardiac failure accompanied by reduced left ventricle ejection fraction.\n7. Electrolyte disturbances, particularly hypokalaemia, hypocalcaemia or hypomagnesaemia.\n8. Any treatment which can induce a lengthening of QT interval, such as:\n\n   1. Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide, procainamide, quinidine, hydroquinidine, sotalol),\n   2. Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine, haloperidol, mesoridazine, pimozide, or thioridazine),\n   3. Anti-depressive agents, certain antimicrobial agents, including agents of the following classes macrolides (e.g. erythromycin, clarithromycin), fluoroquinolones (e.g. moxifloxacin, sparfloxacin), imidazole and triazole antifungal agents, and also pentamidine and saquinavir,\n   4. Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine), cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl, methadone, vinca alkaloids, arsenic trioxide.\n   5. Anti-emetics with known QT prolongation potential such as domperidone\n9. Mixed Plasmodium infection\n10. Severe vomiting, defined as more than three times in the 24 hours prior to enrolment in the study or inability to tolerate oral treatment, or severe diarrhoea defined as 3 or more watery stools per day\n11. Severe malnutrition (defined for subjects aged ten years or less as the weight-for-height being below -3 standard deviation or less than 70% of median of the National Centre for Health Statistics (NCHS)/WHO normalised reference values, and for subjects aged greater than ten years, a body mass index (BMI) of less than 16 (WFP Manual, Chapter 1)).\n12. Known history of hypersensitivity, allergic or adverse reactions to piperaquine or other aminoquinolones or to OZ439 or OZ277\n13. Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody (HCV Ab).\n14. If Total Bilirubin is normal, exclude the patient if liver function tests Aspartate transaminase (AST)/ Alanine transaminase (ALT) ≥ 2x Upper limit of normal (ULN).\n15. If Total Bilirubin is \\> 1 and ≤ 1.5xULN, exclude the patient if AST/ALT \\>1.5xULN.\n16. Total Bilirubin \\> 1.5XULN\n17. Haemoglobin level below 8 g/dL.\n18. Serum creatinine levels ≥2 x ULN\n19. Female patients of child bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures not to become pregnant during the study period and safety follow-up period.\n20. Have received an investigational drug within the past 4 weeks.\n21. Previous participation in any malaria vaccine study or received malaria vaccine in any other circumstance.","healthyVolunteers":false,"sex":"ALL","minimumAge":"6 Months","maximumAge":"70 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population (All Patients)","description":"Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).\n\n95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.8","spread":null},{"groupId":"OG001","value":"68.4","spread":null},{"groupId":"OG002","value":"78.6","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"64","spread":null},{"groupId":"OG002","value":"70.4","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"72.8","spread":null},{"groupId":"OG001","value":"69.6","spread":null},{"groupId":"OG002","value":"81.1","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Africa (> Than 5 Years)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77.8","spread":null},{"groupId":"OG001","value":"90.5","spread":null},{"groupId":"OG002","value":"89.5","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Africa (< = 5 Years)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"71.4","spread":null},{"groupId":"OG001","value":"63.4","spread":null},{"groupId":"OG002","value":"78.9","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>2 to <= 5 Years)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"75.6","spread":null},{"groupId":"OG001","value":"74.0","spread":null},{"groupId":"OG002","value":"83.6","spread":null}]}]}]},{"type":"PRIMARY","title":"PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>= 0.5 to <= 2 Years)","description":"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.\n\n95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.1","spread":null},{"groupId":"OG001","value":"38.1","spread":null},{"groupId":"OG002","value":"62.5","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR - Adjusted ACPR at Day 42 in the PP Population","description":"PCR - adjusted adequate clinical and parasitological response at Day 42","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.0","spread":null},{"groupId":"OG001","value":"65.7","spread":null},{"groupId":"OG002","value":"72.0","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-adjusted ACPR at Day 63 in the PP Population","description":"PCR-adjusted adequate clinical and parasitological response at Day 63","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.8","spread":null},{"groupId":"OG001","value":"58.9","spread":null},{"groupId":"OG002","value":"69.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 28 in the PP Population","description":"Crude adequate clinical and parasitological response at Day 28","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57.4","spread":null},{"groupId":"OG001","value":"56.6","spread":null},{"groupId":"OG002","value":"66.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 42 in the PP Population","description":"Crude adequate clinical and parasitological response at Day 42","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"48.0","spread":null},{"groupId":"OG001","value":"48.5","spread":null},{"groupId":"OG002","value":"51.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 63 in the PP Population","description":"Crude adequate clinical and parasitological response at Day 63","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"39.3","spread":null},{"groupId":"OG002","value":"49.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-adjusted ACPR at Day 28 in the ITT Population","description":"PCR-adjusted adequate clinical and parasitological response at Day 28. Intent to Treat ( ITT) population.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.8","spread":null},{"groupId":"OG001","value":"55.4","spread":null},{"groupId":"OG002","value":"65.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-adjusted ACPR at Day 42 in the ITT Population","description":"PCR-adjusted adequate clinical and parasitological response at Day 42 in the ITT population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"46.9","spread":null},{"groupId":"OG001","value":"48.6","spread":null},{"groupId":"OG002","value":"50.0","spread":null}]}]}]},{"type":"SECONDARY","title":"PCR-adjusted ACPR at Day 63 in the ITT Population","description":"PCR-adjusted adequate clinical and parasitological response at Day 63 in the ITT population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"38.6","spread":null},{"groupId":"OG002","value":"43.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 28 in the ITT Population","description":"Crude adequate clinical and parasitological response at Day 28 in the ITT population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.1","spread":null},{"groupId":"OG001","value":"53.4","spread":null},{"groupId":"OG002","value":"63.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 42 in the ITT Population","description":"Crude adequate clinical and parasitological response at Day 42 in the ITT population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.1","spread":null},{"groupId":"OG001","value":"44.6","spread":null},{"groupId":"OG002","value":"46.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Crude ACPR at Day 63 in the ITT Population","description":"Crude adequate clinical and parasitological response at Day 63 in the ITT population","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.8","spread":null},{"groupId":"OG001","value":"35.0","spread":null},{"groupId":"OG002","value":"43.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of Recurrence","description":"Kaplan-Meier estimate of number of recurrent infections (either recrudescence or new infection)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"44.7","spread":null},{"groupId":"OG001","value":"54.6","spread":null},{"groupId":"OG002","value":"43.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of Recrudescence","description":"Kaplan-Meier estimate of number of patients with recrudescence","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"29.1","spread":null},{"groupId":"OG002","value":"18.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Kaplan-Meier Estimate of New Infection Rate","description":"Kaplan-Meier estimate of number of patients with new infections","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3","spread":null},{"groupId":"OG001","value":"16.3","spread":null},{"groupId":"OG002","value":"13.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Parasite Clearance Time","description":"Time post dose to parasite clearance","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.1","spread":null},{"groupId":"OG001","value":"36.0","spread":null},{"groupId":"OG002","value":"36.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Fever Clearance Time","description":"Time to fever clearance (hours)","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"1.1","spread":null}]}]}]},{"type":"SECONDARY","title":"PRR48","description":"Parasite reduction ratio at 48 hours post dose","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.120","spread":null},{"groupId":"OG001","value":"9.300","spread":null},{"groupId":"OG002","value":"8.690","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Piperaquine: Cday7 Asia (All Ages)","description":"Piperaquine concentration at Day7 in Asian patients all ages","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.2","spread":"72"},{"groupId":"OG001","value":"6.9","spread":"61"},{"groupId":"OG002","value":"9.3","spread":"78"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Piperaquine: Cday7 Africa (> 5 Years)","description":"Piperaquine concentration at Day7 in African patients \\> 5 years","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","spread":"113"},{"groupId":"OG001","value":"8.8","spread":"105"},{"groupId":"OG002","value":"12.1","spread":"103"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Piperaquine: Cday7 Africa (>2 to <= 5 Years)","description":"Piperaquine concentration at Day7 in African patients \\> 2 and \\<= 5years","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.3","spread":"71"},{"groupId":"OG001","value":"9.2","spread":"87"},{"groupId":"OG002","value":"10.9","spread":"92"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Piperaquine: Cday7 Africa (>=0.5 to <= 2 Years)","description":"Piperaquine concentration at Day7 in African patients \\>= 0.5 and \\<= 2 years","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","spread":"63"},{"groupId":"OG001","value":"5.9","spread":"70"},{"groupId":"OG002","value":"9.0","spread":"94"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Artefenomel Cday7 Asian Patients (All Ages)","description":"Artefenomel concentration on Day 7 in Asian Patients (all ages). All Treatment arms.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.1","spread":"95"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Artefenomel Cday7 African Patients (> 5 Years)","description":"Artefenomel concentration on Day 7 in African Patients \\> 5 years. All Treatment arms.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"141"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Artefenomel Cday7 African Patients (>2 to <= 5 Years)","description":"Artefenomel concentration on Day 7 in African Patients \\>2 to \\<= 5 years. All Treatment arms.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":"142"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Artefenomel Cday7 African Patients (>=0.5 to <= 2 Years)","description":"Artefenomel concentration on Day 7 in African Patients \\>= 0.5 to \\<=2 years. All Treatment arms.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":"147"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":146},"commonTop":["malaria","Electrocardiumgram QT prolonged","Diarrhoea","Vomiting","Neutrophil count decreased"]}}}